Compare ACET & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACET | BAFN |
|---|---|---|
| Founded | 1947 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.5M | 40.6M |
| IPO Year | N/A | N/A |
| Metric | ACET | BAFN |
|---|---|---|
| Price | $0.54 | $7.90 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 5.6K |
| Earning Date | 11-05-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.02% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $58,931,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.45 | $6.40 |
| 52 Week High | $1.12 | $19.75 |
| Indicator | ACET | BAFN |
|---|---|---|
| Relative Strength Index (RSI) | 35.12 | 34.84 |
| Support Level | $0.50 | $8.05 |
| Resistance Level | $0.57 | $8.07 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 18.38 | 0.00 |
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.